(Amlodipine maleate + rosuvastatin calcium + telmisartan) is under clinical development by Daewon Pharmaceutical and currently in Phase III for Dyslipidemia. According to GlobalData, Phase III drugs for Dyslipidemia have a 34% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how (Amlodipine maleate + rosuvastatin calcium + telmisartan)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

(Amlodipine maleate + rosuvastatin calcium + telmisartan) overview

DW-1501 is under development for the treatment of hypertension and dyslipidemia. The drug candidate is a fixed dose combination of telmisartan, amlodipine maleate and rosuvastatin calcium. The tehrapeutic candidate is administered through oral route and is incrementally modified drug (IMD). Telmisartan targets angiotensin receptor, amlodipine acts by targeting calcium channel and rosuvastatin targets HMG-CoA reductase enzyme.

Daewon Pharmaceutical overview

Daewon Pharm Co Ltd (Daewon) is a Pharmaceutical company. It manufactures and supplies pharmaceutical and medicinal products. The company offers antipyretics, analgesics and anti-inflammatory drugs, antimicrobial drugs, respiratory drugs, cardiovascular drugs, gastrointestinal drugs, and antidiabetic drugs. Daewon provides oramin-f soft capsule, pelubi tablet, aquafol injection, megex-i suspension, trigel suspension and tablet, and metran capsule. The company offers products in form of tablets, solutions, film coated tablets, hard capsules, vial and ampoule, soft capsules, and sugar coated tablets. Daewon conducts research in areas of DDS research, drug efficacy evaluation research, synthesis molecules, and botanical drug research, and biologics research. The company markets its products in China, Vietnam, Taiwan, Singapore, Hong Kong, Japan, Mongolia, Malaysia, Cambodia, Myanmar, South Korea, the Philippines, and Indonesia, among others. Daewon is headquartered in Seoul, South Korea.

For a complete picture of (Amlodipine maleate + rosuvastatin calcium + telmisartan)’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.